
Enzene Biosciences has introduced Cetuximab, the first biosimilar for cancer treatment. Marketed as Erbitux, Cetuximab is a chimeric monoclonal antibody used as targeted therapy for metastatic colorectal cancer (mCRC) and head and neck cancer. Manufactured using Enzene Biosciences' patented continuous manufacturing platform, this biosimilar aims to significantly reduce treatment costs for Indian patients. By binding to cancer cell surface receptors (EGFR) and inhibiting epidermal growth factor (EGF) binding, Cetuximab functions as a growth and metastasis inhibitor. The biosimilar is expected to be available at a much lower cost than the original biologic, providing an affordable option for patients in India.
Like
Save
Share